Switch theme
Sign up to access all valuation multiples
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis. It operates only in the UK and has only one geographical area.
2018
27
Last FY Revenue $0.1M
Last FY EBITDA -$8.7M
$19.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Celadon Pharma achieved revenue of $0.1M and an EBITDA of -$8.7M.
Celadon Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celadon Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$8.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -8521% | XXX | XXX | XXX |
| EBIT | XXX | -$8.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -8288% | XXX | XXX | XXX |
| Net Profit | XXX | -$9.7M | XXX | XXX | XXX |
| Net Margin | XXX | -9520% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Celadon Pharma's stock price is GBP 0 (or $0).
Celadon Pharma has current market cap of GBP 9.2M (or $12.6M), and EV of GBP 14.0M (or $19.1M).
See Celadon Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19.1M | $12.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Celadon Pharma has market cap of $12.6M and EV of $19.1M.
Celadon Pharma's trades at 341.2x EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Celadon Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celadon Pharma's P/E ratio is not available.
See valuation multiples for Celadon Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.6M | XXX | $12.6M | XXX | XXX | XXX |
| EV (current) | $19.1M | XXX | $19.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 341.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCeladon Pharma's revenue per employee in the last FY averaged $4K, while opex per employee averaged $0.3M for the same period.
Celadon Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celadon Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Celadon Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8388% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celadon Pharma acquired XXX companies to date.
Last acquisition by Celadon Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Celadon Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Celadon Pharma founded? | Celadon Pharma was founded in 2018. |
| Where is Celadon Pharma headquartered? | Celadon Pharma is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Celadon Pharma have? | As of today, Celadon Pharma has 27 employees. |
| Who is the CEO of Celadon Pharma? | Celadon Pharma's CEO is Mr. James Gareth Short. |
| Is Celadon Pharma publicy listed? | Yes, Celadon Pharma is a public company listed on LON. |
| What is the stock symbol of Celadon Pharma? | Celadon Pharma trades under CEL ticker. |
| When did Celadon Pharma go public? | Celadon Pharma went public in 2022. |
| Who are competitors of Celadon Pharma? | Similar companies to Celadon Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celadon Pharma? | Celadon Pharma's current market cap is $12.6M |
| Is Celadon Pharma profitable? | Yes, Celadon Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
